Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Studied

Randomized cardiovascular-safety trial comparing semaglutide with placebo, tracking cardiovascular death, nonfatal heart attack or stroke.

Who / model

3297 people with type 2 diabetes, treated for 104 weeks. Most had cardiovascular disease, chronic kidney disease or both.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The primary outcome occurred in 6.6% versus 8.9%, meeting the trial's cardiovascular-safety criterion. Cardiovascular death rates were similar. Nonfatal strokes were fewer, but heart attacks showed no statistically clear difference. Kidney complications were fewer, while diabetic-eye complications were more frequent. Serious adverse events were fewer overall, but more participants stopped treatment, mainly for digestive symptoms.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary